Marksans Pharma Ltd
MARKSANS
Company Profile
Business description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Contact
Veera Desai Extension Road
11th Floor, Grandeur
Opposite Gundecha Symphony
Oshiwara, Andheri (West)
MumbaiMH400053
INDT: +91 2240012000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2025
Employees
815
Stocks News & Analysis
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
stocks
Undervalued ASX share hampered by delays in foreign expansion
A near monopoly in Australia pushes this company into global markets but progress has been slow.
stocks
Ask the analyst: Why has MinRes fallen so far?
Mineral Resources shares are down almost 50% year to date. Mark Taylor weighs in on some of the reasons why.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,515.20 | 3.70 | -0.04% |
| CAC 40 | 7,226.98 | 199.90 | -2.69% |
| DAX 40 | 19,033.64 | 414.96 | -2.13% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,025.77 | 99.42 | -1.22% |
| HKSE | 19,846.88 | 580.05 | -2.84% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
| NZX 50 Index | 12,660.11 | 89.25 | -0.70% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
| SSE Composite Index | 3,421.97 | 48.10 | -1.39% |